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OBJECTIVE—Fibroblast growth factor 21 (FGF21) is a key
mediator of fatty acid oxidation and lipid metabolism. Pharma-
cological doses of FGF21 improve glucose tolerance, lower
serum free fatty acids, and lead to weight loss in obese mice.
Surprisingly, however, FGF21 levels are elevated in obese ob/ob
and db/db mice and correlate positively with BMI in humans.
However, the expected beneﬁcial effects of endogenous FGF21
to increase glucose tolerance and reduce circulating triglycerides
are absent in obesity.
RESEARCH DESIGN AND METHODS—To test the hypothe-
sis that obesity is a state of FGF21 resistance, we evaluated the
response of obese mice to exogenous FGF21 administration. In
doing this, we assessed the impact of diet-induced obesity on
FGF21 signaling and resultant transcriptional events in the liver
and white adipose tissue. We also analyzed the physiologic
impact of FGF21 resistance by assessing serum parameters that
are acutely regulated by FGF21.
RESULTS—When obese mice are treated with FGF21, they
display both a signiﬁcantly attenuated signaling response as
assessed by extracellular mitogen-activated protein kinase 1 and
2 (ERK1/2) phosphorylation as well as an impaired induction of
FGF21 target genes, including cFos and EGR1. These effects
were seen in both liver and fat. Similarly, changes in serum
parameters such as the decline in glucose and free fatty acids are
attenuated in FGF21-treated DIO mice.
CONCLUSIONS—These data demonstrate that DIO mice have
increased endogenous levels of FGF21 and respond poorly to
exogenous FGF21. We therefore propose that obesity is an
FGF21-resistant state. Diabetes 59:2781–2789, 2010
F
ibroblast growth factor 21 (FGF21) has emerged
as a key mediator of the fasted state and contrib-
utes to regulating lipolysis in white adipose tis-
sue (WAT) (1–3) as well as increasing substrate
utilization by increasing fatty acid oxidation in the liver
(4). In addition, other studies have found that FGF21
increases insulin-independent glucose uptake in 3T3L1
adipocytes. Treatment of ob/ob mice with pharmacologic
doses of FGF21 leads to improved glucose tolerance and
reduced serum triglycerides (5). Subsequent studies have
reported that chronic treatment of diet-induced obese
(DIO) mice with FGF21 also leads to an improved meta-
bolic proﬁle (6,7). A similar effect has been reported in
diabetic monkeys (8). Consistent with its actions on lipid
oxidation in the liver and lipolysis in WAT, mice lacking
FGF21 demonstrate a phenotype of mild obesity and an
atypical response to feeding of a ketogenic diet (9).
FGF21 binds to isoforms of FGF receptor 1, 2, 3, and 4
(10–12) in the presence of a critical co-receptor termed
“Klotho.” This leads to rapid dimerization and autophos-
phorylation of the FGF receptor, which recruits and
activates the ras/raf MAP kinase signaling cascade. This
ultimately leads to activation of extracellular mitogen-
activated protein kinase 1 and 2 (ERK1/2), which translo-
cates to the nucleus and activates a subset of transcription
factors. Part of this process is activation of transcription
factors that regulate elements of the serum response,
leading to induction of immediate early gene expression. It
is now well established that exogenous treatment of
FGF21 leads to a rapid induction of ERK1/2 phosphoryla-
tion in adipose tissue depots (13–15). In addition, our lab
and others (15) have found similar results in the liver.
The wealth of data on this peptide suggests that FGF21
may be an excellent candidate molecule for therapeutic
treatment of diabetes and cardiovascular disease associ-
ated with obesity. It is therefore surprising that in obese
states, which are typically associated with glucose intol-
erance, serum FGF21 levels are high. In fact, in both
rodent diet-induced obese (DIO) (16) and in genetically
obese db/db (17) and ob/ob mice, FGF21 expression is
increased in WAT and liver (18). In addition, in humans,
circulating FGF21 levels were found to correlate positively
with BMI (17,19). This increase in circulating levels is seen
in the context of impaired glucose tolerance and increased
accumulation of lipid in the liver. This suggests that, in the
obese state, FGF21 fails to exert its expected effects on
glucose homeostasis and lipid oxidation. Consistent with
this, a recent article found that acute continuous infusion
of FGF21 to control mice leads to reduced hepatic glucose
output and increased insulin sensitivity while having no
effect on obese ob/ob mice (20). These data have led us to
hypothesize that obesity is an FGF21-resistant state.
To test this hypothesis, we examined the effects of
exogenous FGF21 on signal transduction and gene
expression in the liver and WAT of DIO and lean mice.
We found that DIO mice display a severely impaired
signaling response to FGF21 and an attenuated effect to
induce expression of target genes. In addition, low-dose
FGF21 treatment was associated with an impaired im-
provement in serum parameters in the DIO mice. These
ﬁndings are consistent with obesity being an FGF21-
resistant state.
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Animals. All studies were carried out using male C57Bl6 mice obtained from
The Jackson Laboratory (Bar Harbor, ME) and maintained at 24°C on a 12:12-h
light-dark cycle. For DIO studies, mice were placed on an obesogenic
high-fat/high-sucrose diet (Research Diets, New Brunswick, NJ) for 22 weeks
to achieve a gain of an average of 10 g. Mice were acclimated to excessive
handling for at least 10 days before experimentation. All studies were
approved by the Beth Israel Deaconess Medical Center Institutional Animal
Care and Use Committee (IACUC).
FGF21 protein. Human recombinant FGF21 was expressed in Escherichia
coli and refolded in vitro as previously described (5).
Analysis of FGF21 signaling. For analysis of acute signaling events in the
liver and WAT, FGF21 was administered via the inferior vena cava to
anesthetized adult mice. In brief, mice were anesthetized via intraperitoneal
injection of a ketamine/xylazene cocktail. The peritoneal cavity was then
exposed and either FGF21 or saline was injected directly into the inferior vena
cava in a total volume of 20 l. After 10 min, the liver and perigonadal adipose
tissue were dissected, ﬂash-frozen, and stored at 80°C. Protein was ex-
tracted using a radioimmunoprecipitation assay buffer and assessed using a
Western blotting technique. After processing, blots were probed using anti-
bodies against pERK1/2 (Cell Signaling, Danvers, MA) and ERK1/2 (AbCam,
Cambridge, MA).
Analysis of immediate early gene response. To assess immediate early
gene response, mice were injected intraperitoneally with either saline (n  6)
or various doses of recombinant FGF21 (n  6) in a total volume of 200 l.
Mice were then placed back in their home cage without access to food for the
remainder of the experiment. After 2 h, mice were killed. Tissues were
snap-frozen in liquid nitrogen before storage at 80°C. Blood was collected by
cardiac puncture and fractionated using centrifugation at 10,000 rpm for 10
min. Serum was separated and stored at 20°C. Egr1 and cFos mRNA
expression was assessed using quantitative RT-PCR. Egr1 protein expression
was assessed using Western blotting with a primary antibody raised against
Egr1 (Cell Signaling, Danvers, MA).
Quantitative RT-PCR. RNA, from ﬂash-frozen tissue, was extracted using an
RNAeasy lipid tissue kit (Qiagen, Germantown, MD) according to instructions.
A DNAse (Qiagen) digestion step was included to prevent contamination of
genomic DNA. cDNA was generated from 0.5 g RNA, using oligo(dt) and
random hexamer primers and Moloney murine leukemia virus reverse tran-
scriptase (Quantitech RT for PCR; Qiagen), and diluted 10-fold to 0.5 ml.
Quantitative PCR was performed using the 7800HT (Applied Biosystems,
Foster City, CA) thermal cycler and SYBR Green master mix (Applied
Biosystems). Expression of each target gene was quantiﬁed by transformation
against a standard curve and normalized to cyclophilin expression unless
otherwise stated. Primers were designed using Primer3 online software (Open
Source) and obtained from Invitrogen (Carlsbad, CA) as detailed in supple-
mental Table 1 (available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0193/DC1).
Western blotting. In brief, tissues were homogenized in radioimmunopre-
cipitation assay buffer (150 mmol/l NaCl, 1.0% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mmol/l Tris, pH 8.0) supplemented with a Complete Mini
Protease Inhibitor Cocktail (Roche, Basel, Switzerland) and phosphatase
inhibitors. Protein concentrations were determined with BCA protein assay
(Pierce, Thermo Scientiﬁc). A total of 20 g protein was analyzed by
SDS-PAGE on a 4–15% Criterion Tris/HCl gel (Bio-Rad, Hercules, CA) and
transferred onto nitrocellulose (Protran; Schleicher and Schuell, Keene, NH).
Blots were then probed with each speciﬁed primary antibody, and the blots
were developed with Super Signal West Pico chemiluminescent reagent
(Pierce, Thermo Scientiﬁc, Rockford, IL).
Serum hormones and metabolites. Blood samples were collected on ice
and either heparinized or spun at room temperature before storage of plasma
at 4°C or allowed to clot and spun at 4°C before ﬂash-freezing of serum in
liquid nitrogen. Serum metabolites were measured by small-scale enzymatic
assay for glucose (Stanbio Laboratory, Boerne, TX) and nonesteriﬁed fatty
acids (NEFAs) (Wako Diagnostics, Richmond, VA). Endogenous FGF21 levels
were determined by a speciﬁc mouse enzyme-linked immunosorbent assay
(ELISA) (BioVendor, Candler, NC) and exogenous levels assessed using a
speciﬁc human ELISA (BioVendor).
Statistical analysis. Data are displayed as the mean  SE. Comparisons
between groups were analyzed using ANOVA (Prism, Graphpad, La Jolla, CA),
where P  0.05 was considered statistically signiﬁcant.
RESULTS
Diet-induced obese mice have elevated circulating
levels of FGF21. Because increased FGF21 levels have
been reported in genetically obese mice and obese hu-
mans, we assessed serum and liver and WAT mRNA levels
in mice with diet-induced obesity. We found a 20-fold
increase in liver mRNA expression of FGF21 (Fig. 1A; lean
1.13  0.29; obese 21.72  3.18; P  0.0001). A signiﬁcant
but less dramatic twofold increase was observed in mRNA
expression in perigonadal WAT (Fig. 1B; lean 0.88  0.16;
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FIG. 1. Circulating levels of FGF21 are increased in mice with
diet-induced obesity. Analysis of FGF21 mRNA expression in diet-
induced obese mice is shown. mRNA expression was quantiﬁed using
a standard quantitative PCR technique. Data are shown from the
liver (A) and WAT (B). C: Circulating FGF21 levels were determined
with the use of an ELISA in serum from a terminal bleed. Data are
displayed as the mean  SE. ***P < 0.001.
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expression mRNA in both of these tissues, serum FGF21
levels were elevated in obese mice (Fig. 1C; lean 604.2 
62.85 pg/ml; obese 2,315  269.7 pg/ml; P  0.0001).
FGF21 signaling is attenuated in liver and WAT of
obese mice. FGF21 reduces circulating NEFAs and tri-
glycerides and enhances glucose tolerance; however, there
were no apparent beneﬁcial effects of the increased circu-
lating levels of FGF21 in the obese animals. This is
consistent with our hypothesis that obese mice are resis-
tant to FGF21. To test this hypothesis, we assessed the
ability of FGF21 to recruit FGF signaling pathways in the
liver and WAT of obese mice. In this experiment, we used
ERK1/2 phosphorylation as a reporter of FGF signaling.
We found that at low doses (25 and 50 ng/g), there was a
severe impairment in the ability of FGF21 to activate
signaling pathways in obese mice (Fig. 2A) characterized
by a reduced level of hepatic ERK1/2 phosphorylation.
Because WAT is also a target of FGF21 action, we assessed
ERK1/2 phosphorylation in perigonadal WAT (25, 50, and
100 ng/g) and found reduced phosphorylation of ERK1/2 in
WAT of obese mice (Fig. 2B).
Induction of immediate early gene expression down-
stream of FGF21 signaling is impaired in obese mice.
Phosphorylation of ERK1/2 leads to its translocation into
the nucleus, where it phosphorylates and activates a
subset of transcription factors. Among these are elements
regulating the “serum response” that include rapid tran-
scription of immediate early gene expression (21). To
conﬁrm FGF21 resistance, we used this as a secondary
readout for FGF21 action in these tissues. In this experi-
ment, we injected mice with FGF21 or intraperitoneal
saline and assessed immediate genes Egr1 and cFos ex-
pression in the liver and WAT. Egr1 mRNA expression was
robustly increased in the liver of lean mice at the two
higher doses (100 and 200 ng/g) (Fig. 3A). However, there
was no effect of FGF21 administration on Egr1 expression
in the liver of the obese mice. Consistent with this, we saw
no increase in Egr1 protein expression in the liver of the
obese mice, whereas a large increase in protein levels was
seen in lean mice. Again, we saw a markedly attenuated
response in WAT of obese mice, with little induction of
Egr1 expression at any dose tested (Fig. 3B). This was also
conﬁrmed with Western blotting, where increases in Egr1
protein levels were only observed in the WAT from the
lean mice. Induction of cFos mRNA expression was not as
responsive to FGF21 treatment; nevertheless, the effect
seen in obese mice was attenuated to that seen in lean
mice compared with obese mice (Fig. 3C). This was also
the case in WAT (Fig. 3D).
Impaired reduction in circulating glucose and NEFAs
in response to low-dose FGF21 administration in
obese mice. Administration of FGF21 leads to acute
reduction in circulating glucose and NEFAs in mice. To
see if this response is impaired in obese mice, we exam-
ined the effect of a dose of 200 ng/g of FGF21 on these
parameters. At this dose, FGF21 lowered circulating glu-
cose levels by 17.4% in the lean mice (Fig. 4A; saline
164.4  6.10 mg/dl; FGF21 135.8  7.81 mg/dl; P  0.0211).
Although there was a slight reduction in the obese mice,
this did not reach statistical signiﬁcance (saline 167.6 
10.58 mg/dl; FGF21 153.7  4.98 mg/dl; P  NS). Because
the ability of FGF21 to lower circulating glucose levels is
thought to be due, in part, to increased expression of
GLUT1 in adipose tissue, we assessed GLUT1 mRNA
expression in the WAT of these mice (Fig. 4B). Although
there was a small induction in GLUT1 expression in the
obese mice (1.7-fold, P  0.0048), the response was far
more prominent in the lean mice (2.8-fold, P  0.0003).
In addition to lowering glucose, FGF21 acutely reduces
circulating NEFAs—a phenomenon that was observed in
this study. Serum NEFAs were reduced by FGF21 in the
lean mice by 50% (Fig. 4C; 0.51-fold, P  0.0068); in the
obese mice, the effect was much smaller and levels were
reduced by only 20% (0.79-fold, P  0.0371). FGF21 is
thought to reduce NEFAs in part by attenuating lipolysis in
WAT tissue (2). To see how this was affected in our model
of FGF21 resistance, we looked at mRNA expression of
lipolytic genes in WAT. Hormone-sensitive lipase (HSL)
expression was signiﬁcantly reduced by FGF21 in the lean
mice (Fig. 4D; 0.7-fold, P  0.0015) but not in the obese
mice (0.9-fold, P  NS). This was also the case with
perilipin expression, which was far more suppressed in
the FGF21-treated lean mice (Fig. 4E; 0.71-fold, P  0.028)
than in the obese mice (0.99-fold, P  NS).
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FIG. 2. FGF21 signaling is attenuated in liver and WAT of obese mice.
To test whether FGF21 signaling is impaired in obese mice, we assessed
FGF21-mediated ERK1/2 phosphorylation in the liver (A) and WAT
(B). Results from every Western blot are shown in each case displaying
both the phosphorylated form and total ERK1/2 expression. Above
each blot, the densitometry is shown for all experimental regimes and
is calculated as pERK/total ERK. Data are displayed as the mean  SE.
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WAT of obese mice. To determine whether reduced
expression of FGF21 receptors might contribute to the
attenuated FGF21 signaling in obese mice, we assessed
FGF21 receptor and co-receptor expression in the liver
and WAT from obese and lean mice. There does not seem
to be any effect of obesity on Klotho expression in the
liver of obese mice (Fig. 5A). In addition, the expression of
the majority of FGF receptors was unaffected by obesity in
this tissue. However, there was a signiﬁcant reduction in
the expression of FGFR1 in the liver of obese mice
compared with lean mice (lean 0.021  0.0026; obese
0.0069  0.00064; P  0.0004).
In WAT, obesity was associated with substantial effects
on receptor expression. FGFr1, the most abundant recep-
tor in WAT, was reduced by almost 50% in obese mice (Fig.
5B; lean 2.18  0.10; obese 1.24  0.17; P  0.0007). In
addition, both FGFr2 (lean 0.12  0.012; obese 0.042 
0.0027; P  0.0001) and FGFr3 (lean 0.024  0.0034; obese
0.0075  0.00081; P  0.0008) expression was signiﬁcantly
reduced in WAT from obese mice. Expression of the
co-receptor Klotho, which has been found to be a critical
component of FGF21 signaling, was also down by 44%
(lean 0.42  0.037; obese 0.23  0.013, P  0.0008).
Obese FGF21 KO mice are phenotypically similar to
wild-type mice. Because we have previously reported
that chow-fed FGF21 KO mice are heavier than chow-
fed WT mice, we investigated the effect of diet-induced
obesity on FGF21 KO mice. Although WT mice have
substantially increased levels of circulating FGF21,
there is little phenotypic difference between WT animals
compared with obese FGF21 KO mice. The signiﬁcant
difference in adiposity between chow-fed WT mice and
FGF21 KO mice (Fig. 6A; P  0.033) disappears once
they are placed on an obesogenic diet (Fig. 6A; P 
0.11). In addition, chow-fed FGF21 KO mice were more
glucose intolerant than wild-type animals with reduced
glucose excursion during a glucose tolerance test (Fig.
6B; P  0.013). This difference was not observed in the
mice ingesting a high-fat diet (Fig. 6B; P  0.85). Circu-
lating NEFAs were also signiﬁcantly elevated
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FIG. 3. Induction of immediate early gene expression downstream of FGF21 signaling is impaired in obese mice. To conﬁrm whether FGF21
signaling is impaired in obese mice, we assessed immediate early gene expression downstream of ERK in obese and lean mice. Both mRNA
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which was not observed between the mice on a high-fat
diet.
FGF21 resistance manifests early during weight gain.
FGF21 administration leads to weight loss in rodents, and
its actions are considered anorexigenic (6). As our initial
studies have all been carried out in mice with established
obesity, we carried out a longitudinal study to see whether
FGF21 resistance precedes obesity. To do this, we ana-
lyzed two cohorts of mice fed a high-fat diet for either 7
days or 4 weeks. After 7 days on a high-fat diet, the mice
had not gained weight (supplemental Fig. 1A). At this time,
there was no impairment in the induction of FGF21-
responsive genes in the liver (supplemental Fig. 1B)o r
WAT (supplemental Fig. 1C and D). Mice fed a high-fat diet
for 4 weeks had gained an average of 2.5 g (Fig. 7A). This
was associated with an impaired induction of EGR1 in the
liver (Fig. 7B) but not in WAT (Fig. 7C). However, there
was an attenuated response in FGF21-mediated GLUT1
expression in WAT in these mice (Fig. 7C). FGF21 liver
and WAT expression was not signiﬁcantly increased by
high-fat diet at either of these early time points (data not
shown).
DISCUSSION
It is now clear that increased tissue expression and serum
levels of FGF21 are associated with the obese state. Levels
are increased in genetically obese ob/ob (18) and db/db
(17) mice. In humans, serum levels correlate with BMI
(22). We found that levels are also increased in rodents
with diet-induced obesity. Interestingly, despite high en-
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FIG. 4. FGF21 has an impaired capacity to reduce serum glucose and
NEFAs in obese mice. To analyze the impact of obesity-associated
FGF21 resistance on the physiologic improvements we associate with
FGF21 action, we looked at serum parameters that are acutely regulated
by FGF21. The effect of FGF21 treatment on circulating glucose (A) and
NEFAs (C) are shown in lean and obese mice. mRNA expression for
genes regulating these parameters is also shown from epididymal WAT:
GLUT1 (B), HSL (D), and perilipin (E). Data are displayed as the
mean  SE. *P < 0.05; **P < 0.01; ***P < 0.001. f, Lean; , obese.
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istered at pharmacologic doses appears to exert actions to
improve metabolic parameters and induces weight loss
(6,7). A state in which high endogenous levels of a
physiologic regulator appear to be ineffective but in which
high pharmacologic doses induce the expected results
suggests a state of hormone resistance.
The concept of hormone resistance dates back more
than half a century when insulin resistance was noted in
patients with diabetes receiving insulin and was attributed
to the development of neutralizing antibodies (23). Insulin
resistance was subsequently described in the ob/ob mouse
when it was noted that these mice were resistant to the
glucose-lowering effects of exogenous insulin, even when
pair-fed to maintain a normal body weight (24). By the
early 1960s, obesity was found to be associated with
endogenous hyperinsulinemia in humans in an “apparent
paradox” (25). Subsequent studies led to a mechanistic
understanding that implicate downregulation of the insulin
receptor (26), decreased insulin receptor kinase activity
(27), and multiple intracellular deﬁcits as well as increased
expression of PTP1B (28). Similarly, obesity has been
identiﬁed as a state of leptin resistance (29) in which high
circulating levels fail to induce the desired physiologic
effect of decreased feeding, in part through induction of
the leptin-regulating antagonist SOCS3 (30).
As we demonstrate in this article, obesity is also a state
of FGF21 resistance. In response to FGF21, obese mice
demonstrate marked deﬁcits in the ability of the peptide to
initiate signals through the ras-raf-MAPK cascade, as dem-
onstrated by the remarkably low levels of ERK1/2 phos-
phorylation in liver and WAT. We also show that the ability
of FGF21 to induce the expected changes in the expres-
sion of the immediate early genes Egr1 and cFos was
signiﬁcantly decreased. This effect was seen at both the
mRNA and protein levels in both liver and WAT. To ensure
that these results were not due to inadequate dosing of
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(B) (*signiﬁcance by repeated-measure ANOVA), and circulating NEFAs
in each group (C) are shown. Data are displayed as the mean  SE. *P <
0.05.
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FIG. 5. FGF receptor and Klotho expression is reduced in WAT of
obese mice. FGF21 binds to and activates multiple subtypes of the FGF
receptor family in the presence of the co-receptor Klotho. To see
whether FGF receptor and Klotho expression is reduced in obese
mice, we assessed mRNA levels in the liver (A) and WAT (B) of lean
and obese mice. Data for each gene are calculated using 36B4 as a
reference gene, and data are transformed using the formula 2
Ct.
Data are means  SE. ***P < 0.001.
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FGF21 by ELISA (supplemental Fig. 1) and found that in
fact our dosing scheme led to somewhat higher levels of
FGF21 in obese mice.
Furthermore, we were able to show that resistance
extends to physiologic actions of FGF21. Initial studies of
FGF21 found that it acutely increased glucose uptake into
adipocytes, which may have been one of the mechanisms
contributing to lower circulating glucose levels in mice
(5). This is thought to occur through FGF21’s ability to
increase the expression of the GLUT1 in adipocytes. Data
from this study show that, in obese mice, the glucose-
lowering effect of FGF21 is also impaired; FGF21 admin-
istration leads to a signiﬁcant reduction in circulating
glucose levels only in lean mice. This was associated with
impaired induction of GLUT1 expression in fat, which rose
3-fold in lean mice and only 1.8-fold in obese mice.
Another physiologic effect of FGF21 is to acutely lower
circulating levels of free fatty acids (FFAs). This is thought
to occur through the ability of FGF21 to reduce rates of
lipolysis in WAT (2,3). As can been seen from our data,
minimal doses of FGF21 dramatically lowered circulating
FFAs in the lean mice. Although there was a statistically
signiﬁcant reduction in the obese mice, it was small in
comparison. To determine whether this was due to atten-
uated lipolytic gene expression, we evaluated HSL and
perilipin mRNA levels in WAT. Consistent with reduced
circulating FFAs, we found that FGF21 caused a signiﬁ-
cant reduction in the expression of WAT lipolytic gene
expression in the lean mice. In the DIO mice, the small
reduction in FFAs in response to FGF21 was associated
with only a minimal effect on HSL and perilipin expres-
sion, which did not reach statistical signiﬁcance. Although
these enzymes are also allosterically regulated, the effect
of FGF21 to reduce lipolytic gene expression could con-
tribute to the reduced circulating FFAs.
Our data comparing wild-type mice with mice with
genetic ablation of FGF21 also support the concept of
FGF21 resistance through a different approach. When
eating chow, FGF21 KO animals and WT animals have a
distinct phenotype: FGF21 KO animals are slightly heavier
and have impaired glucose tolerance and higher levels of
circulating NEFAs, even in the fasted state. This pheno-
typic consequence of FGF21 deﬁciency disappears when
WT animals are fed a high-fat diet, since they “acquire” the
phenotype of mice lacking FGF21 despite the rise in
FGF21 levels. Thus, on a high-fat diet, WT and FGF21 KO
animals weigh the same, have the same degree of glucose
tolerance, and have similar circulating NEFA levels. This
clearly indicates that FGF21 ceases to exert a beneﬁcial
metabolic action once obesity is established.
To examine the possible contribution of FGF21 resis-
tance to obesity, we evaluated resistance at several time
points after initiation of a high-fat diet. There was no
evidence of FGF21 resistance in mice fed a high-fat diet for
1 week. At this time, there was no change in FGF21
expression in the liver or WAT. However, mice eating a
high-fat diet for 4 weeks showed an impaired induction of
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FIG. 7. FGF21 resistance manifests early during weight gain. To test whether FGF21 resistance precedes the onset of obesity, mice were fed a high-fat
diet for 4 weeks. At this time, mice were analyzed for FGF21 resistance via acute intraperitoneal injection of 150 ng/g of FGF21. Weights (A), hepatic
FGF21-induced EGR1 expression (B), WAT EGR1 (C), and GLUT1 expression (D) are shown. Data are displayed as the mean  SE. *P < 0.05.
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ment. Although attenuated responses to FGF21 were not
universal, these data suggest FGF21 resistance begins to
manifest early during weight gain. However, we do not
believe that FGF21 resistance is a major cause of obesity
for several reasons. First, FGF21 has little effect on weight
and only causes weight loss at high pharmacologic doses;
FGF21 KO chow-fed mice only display late-onset mild
adiposity. Second, the FGF21 KO mice fed a high-fat diet
gained weight at a similar rate as their WT littermates. If
FGF21 resistance was a cause of obesity, a lag phase
would be expected in the WT weights, as FGF21 resistance
would need to develop ﬁrst before it can contribute to
obesity. Thus, it seems unlikely that FGF21 resistance has
a major contributory role toward the development of
obesity. Nevertheless, FGF21 resistance likely contributes
signiﬁcantly toward the complications associated with
weight gain and obesity, such as glucose intolerance and
elevated circulating NEFAs.
Identifying the precise pathways by which obesity in-
duces FGF21 resistance will require additional work.
Because we observed evidence of FGF21 resistance at
both a signaling and transcriptional level, the mechanisms
regulating this process should be occurring upstream of
ERK1/2. Although hepatic expression of Klotho is un-
changed in the obese state, it is signiﬁcantly decreased in
WAT. In addition, we have seen reduced expression of
FGF receptors including FGFR1 in liver and FGFR1,
FGFR2, and FGFR3 in WAT. This is similar to the down-
regulation of insulin receptors seen in obesity. However,
the mediator of FGF21 resistance remains unknown. The
potential role of phosphatases or other molecules that
might impair signaling through the ERK pathway remains
to be determined. Nevertheless, FGF21 resistance can be
added to the hormone-resistant states observed in obesity.
Understanding the mechanisms of this process could
represent a new target for therapeutic treatment of obesity
and obesity-related diseases.
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